Cargando…
Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma
Accurate differentiation of true progression (TP) from pseudoprogression (PsP) in patients with glioblastomas (GBMs) is essential for planning adequate treatment and for estimating clinical outcome measures and future prognosis. The purpose of this study was to investigate the utility of three‐dimen...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519064/ https://www.ncbi.nlm.nih.gov/pubmed/30556932 http://dx.doi.org/10.1002/nbm.4042 |
_version_ | 1783418575535472640 |
---|---|
author | Verma, Gaurav Chawla, Sanjeev Mohan, Suyash Wang, Sumei Nasrallah, MacLean Sheriff, Sulaiman Desai, Arati Brem, Steven O'Rourke, Donald M. Wolf, Ronald L. Maudsley, Andrew A. Poptani, Harish |
author_facet | Verma, Gaurav Chawla, Sanjeev Mohan, Suyash Wang, Sumei Nasrallah, MacLean Sheriff, Sulaiman Desai, Arati Brem, Steven O'Rourke, Donald M. Wolf, Ronald L. Maudsley, Andrew A. Poptani, Harish |
author_sort | Verma, Gaurav |
collection | PubMed |
description | Accurate differentiation of true progression (TP) from pseudoprogression (PsP) in patients with glioblastomas (GBMs) is essential for planning adequate treatment and for estimating clinical outcome measures and future prognosis. The purpose of this study was to investigate the utility of three‐dimensional echo planar spectroscopic imaging (3D‐EPSI) in distinguishing TP from PsP in GBM patients. For this institutional review board approved and HIPAA compliant retrospective study, 27 patients with GBM demonstrating enhancing lesions within six months of completion of concurrent chemo‐radiation therapy were included. Of these, 18 were subsequently classified as TP and 9 as PsP based on histological features or follow‐up MRI studies. Parametric maps of choline/creatine (Cho/Cr) and choline/N‐acetylaspartate (Cho/NAA) were computed and co‐registered with post‐contrast T (1)‐weighted and FLAIR images. All lesions were segmented into contrast enhancing (CER), immediate peritumoral (IPR), and distal peritumoral (DPR) regions. For each region, Cho/Cr and Cho/NAA ratios were normalized to corresponding metabolite ratios from contralateral normal parenchyma and compared between TP and PsP groups. Logistic regression analyses were performed to obtain the best model to distinguish TP from PsP. Significantly higher Cho/NAA was observed from CER (2.69 ± 1.00 versus 1.56 ± 0.51, p = 0.003), IPR (2.31 ± 0.92 versus 1.53 ± 0.56, p = 0.030), and DPR (1.80 ± 0.68 versus 1.19 ± 0.28, p = 0.035) regions in TP patients compared with those with PsP. Additionally, significantly elevated Cho/Cr (1.74 ± 0.44 versus 1.34 ± 0.26, p = 0.023) from CER was observed in TP compared with PsP. When these parameters were incorporated in multivariate regression analyses, a discriminatory model with a sensitivity of 94% and a specificity of 87% was observed in distinguishing TP from PsP. These results indicate the utility of 3D‐EPSI in differentiating TP from PsP with high sensitivity and specificity. |
format | Online Article Text |
id | pubmed-6519064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65190642019-08-29 Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma Verma, Gaurav Chawla, Sanjeev Mohan, Suyash Wang, Sumei Nasrallah, MacLean Sheriff, Sulaiman Desai, Arati Brem, Steven O'Rourke, Donald M. Wolf, Ronald L. Maudsley, Andrew A. Poptani, Harish NMR Biomed Research Articles Accurate differentiation of true progression (TP) from pseudoprogression (PsP) in patients with glioblastomas (GBMs) is essential for planning adequate treatment and for estimating clinical outcome measures and future prognosis. The purpose of this study was to investigate the utility of three‐dimensional echo planar spectroscopic imaging (3D‐EPSI) in distinguishing TP from PsP in GBM patients. For this institutional review board approved and HIPAA compliant retrospective study, 27 patients with GBM demonstrating enhancing lesions within six months of completion of concurrent chemo‐radiation therapy were included. Of these, 18 were subsequently classified as TP and 9 as PsP based on histological features or follow‐up MRI studies. Parametric maps of choline/creatine (Cho/Cr) and choline/N‐acetylaspartate (Cho/NAA) were computed and co‐registered with post‐contrast T (1)‐weighted and FLAIR images. All lesions were segmented into contrast enhancing (CER), immediate peritumoral (IPR), and distal peritumoral (DPR) regions. For each region, Cho/Cr and Cho/NAA ratios were normalized to corresponding metabolite ratios from contralateral normal parenchyma and compared between TP and PsP groups. Logistic regression analyses were performed to obtain the best model to distinguish TP from PsP. Significantly higher Cho/NAA was observed from CER (2.69 ± 1.00 versus 1.56 ± 0.51, p = 0.003), IPR (2.31 ± 0.92 versus 1.53 ± 0.56, p = 0.030), and DPR (1.80 ± 0.68 versus 1.19 ± 0.28, p = 0.035) regions in TP patients compared with those with PsP. Additionally, significantly elevated Cho/Cr (1.74 ± 0.44 versus 1.34 ± 0.26, p = 0.023) from CER was observed in TP compared with PsP. When these parameters were incorporated in multivariate regression analyses, a discriminatory model with a sensitivity of 94% and a specificity of 87% was observed in distinguishing TP from PsP. These results indicate the utility of 3D‐EPSI in differentiating TP from PsP with high sensitivity and specificity. John Wiley and Sons Inc. 2018-12-17 2019-02 /pmc/articles/PMC6519064/ /pubmed/30556932 http://dx.doi.org/10.1002/nbm.4042 Text en © 2018 The Authors. NMR in Biomedicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Verma, Gaurav Chawla, Sanjeev Mohan, Suyash Wang, Sumei Nasrallah, MacLean Sheriff, Sulaiman Desai, Arati Brem, Steven O'Rourke, Donald M. Wolf, Ronald L. Maudsley, Andrew A. Poptani, Harish Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma |
title | Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma |
title_full | Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma |
title_fullStr | Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma |
title_full_unstemmed | Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma |
title_short | Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma |
title_sort | three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519064/ https://www.ncbi.nlm.nih.gov/pubmed/30556932 http://dx.doi.org/10.1002/nbm.4042 |
work_keys_str_mv | AT vermagaurav threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT chawlasanjeev threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT mohansuyash threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT wangsumei threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT nasrallahmaclean threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT sheriffsulaiman threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT desaiarati threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT bremsteven threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT orourkedonaldm threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT wolfronaldl threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT maudsleyandrewa threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma AT poptaniharish threedimensionalechoplanarspectroscopicimagingfordifferentiationoftrueprogressionfrompseudoprogressioninpatientswithglioblastoma |